During the corresponding time, Esperion Therapeutics Inc recorded a revenue increase by 23.25 % year on year, sequentially revenue fell by -52.45 %. While revenue at the Esperion Therapeutics Inc 's corporate clients
Esperion Therapeutics Inc's Comment on Sales, Marketing and Customers
The marketing, selling, and distribution of the pharmaceutical products NEXLETOL and NEXLIZET are subject to regulatory requirements, including compliance with healthcare laws such as the federal Anti-Kickback Statute and the False Claims Act. Pharmaceutical manufacturers engage with prescribers, purchasers, and formulary managers in their business arrangements. Federal enforcement agencies monitor product and patient assistance programs, including reimbursement and co-pay support services, which can influence the marketing and sales of these products.
NILEMDO, also known as NEXLETOL in the U.S., stands out as a pioneering treatment in the cholesterol-lowering market due to its unique mechanism of action. Bempedoic acid, the active ingredient in NILEMDO, targets and inhibits ATP-citrate lyase (ACL), a key enzyme involved in the hepatic biosynthesis of cholesterol. This process ultimately results in reduced plasma levels of LDL-C, often termed bad cholesterol.
NUSTENDI (marketed as NEXLIZET in the U.S.) offers a powerful combination of bempedoic acid and ezetimibe, another established cholesterol-lowering agent that impedes the absorption of cholesterol in the intestines. Together, these agents provide a synergistic effect in managing LDL-C levels, offering a comprehensive solution for patients grappling with hypercholesterolemia who may not achieve their lipid goals with standard therapies alone.
Clinical trials and real-world evidence have heralded these therapies as safe and effective, fulfilling an urgent need for alternative treatments in the cardiovascular risk reduction arsenal. This label update approval by the European Commission underscores the pivotal role that NILEMDO and NUSTENDI will play in enhancing patient outcomes. Linking Inflammation to Cardiovascular Events
Adding another layer to their robust cardiovascular research, Esperion presented an intriguing prespecified, exploratory analysis at the American Heart Association (AHA) Scientific Sessions 2023. This analysis, part of the CLEAR Outcomes study, examined the correlation between baseline inflammation levels and cardiovascular events among participants.
The study's findings highlighted a critical facet of cardiovascular risk management: individuals with higher baseline levels of inflammation were significantly more prone to experiencing major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality compared to those with the lowest levels of inflammation. This compelling evidence accentuates the role of inflammation as a crucial predictor of cardiovascular risk, reinforcing the necessity for treatments that address both lipid levels and inflammatory pathways to optimize cardiovascular health. The TRANSFORM Trial: Personalizing Heart Disease Care
In tandem with presenting the CLEAR Outcomes analysis, Esperion, along with its partners, announced the initiation of the transformative TRANSFORM Trial at the AHA 2023. This randomized control trial is set to revolutionize the evaluation and treatment of heart disease by focusing on the direct study of atherosclerosis'a leading cause of cardiovascular morbidity and mortality.
The TRANSFORM Trial aims to investigate personalized care strategies in treating heart disease, utilizing advanced diagnostic and therapeutic approaches to tailor interventions based on individual patient profiles. By evaluating the efficacy of personalized care in the management of atherosclerosis, the trial seeks to advance the evidence base and pave the way for more precise and effective cardiovascular therapies.
A Multi-faceted Approach to Cardiovascular Risk Reduction
The European approval of NILEMDO and NUSTENDI, alongside groundbreaking research such as the CLEAR Outcomes analysis and the TRANSFORM Trial, underscores Esperion's commitment to combating cardiovascular disease on multiple fronts. By integrating innovative treatments, predictive inflammation markers, and personalized care strategies, Esperion is poised to make substantial strides in reducing cardiovascular risk and improving patient outcomes worldwide.
These milestones reaffirm the imperative need for continued research and development in cardiovascular therapeutics. As medical science evolves, comprehensive strategies that address various facets of heart disease'cholesterol management, inflammation, and individualized care'will be paramount in achieving long-term health benefits for patients around the globe.
Pioneering Cholesterol-Lowering Treatments NILEMDO and NUSTENDI Receive European Approval to Combat Hypercholesterolemia and AtherosclerosisThe European medical community has recently witnessed a significant breakthrough in the ongoing battle against cardiovascular disease. Esperion Therapeutics, Inc. has announced the European Commission s approval of their first-in-class oral cholesterol-lowering treatment, NILEMDO (bempedoic acid), and its combination with ezetimibe, NUSTENDI (bempedoic acid/ezetimibe fixed-dose combination). These novel treatments are designed to effectively lower low-density lipoprotein cholesterol (LDL-C) levels, address hypercholesterolemia, and significantly mitigate cardiovascular ...
Bempedoic Acid Triumphs in Phase 3 Japanese Trial: A Game-Changer for Hypercholesterolemia TreatmentANN ARBOR, Mich., May 20, 2024 In a groundbreaking announcement today, Esperion Therapeutics, Inc. (Nasdaq: ESPR) along with Otsuka Pharmaceutical Co., Ltd (Otsuka) revealed the successful completion of their Phase 3 trial in Japan for bempedoic acid. This major milestone marks a significant leap forward in the battle against hypercholesterolemia, a condition affecting millions worldwide. Trial Highlights and Primary Endpoint AchievementThe Phase 3 trial, rigorously conducted across multiple high-profile medical centers in Japan, aimed to evaluate the efficacy and safety of bempedoic acid in patients suffer...
The recent presentation of new data from the CLEAR Outcomes trial at ACC.24 has shed light on the potential value of NEXLETOL (bempedoic acid) tablets in reducing the risk of major adverse cardiovascular events (MACE-4) in diverse populations. These populations include women, Hispanics/Latinx individuals, and patients with obesity. This article aims to ly analyze the data presented, highlighting its implications and potential benefits.Key Findings:According to the study findings presented at ACC.24, patients with obesity who took NEXLETOL demonstrated a 23% lower likelihood of experiencing a major adverse cardiovascular event (MACE-4) compared to those given a placebo. This finding points towards the potenti...
Esperion, a leading pharmaceutical company specializing in cardiovascular therapeutics, has recently announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for their novel cholesterol-lowering medications, NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets. This significant development is based on the positive clinical trial results from the CLEAR Outcomes study, which demonstrated the drugs efficacy in reducing cardiovascular events and lowering LDL cholesterol levels. The expanded labels cover both primary and secondary prevention patients, irrespective of their usage of statin medications.The CLEAR Outcomes StudyThe a...
Esperion Therapeutics Inc’s Comment on Sales, Marketing and Customers
The marketing, selling, and distribution of the pharmaceutical products NEXLETOL and NEXLIZET are subject to regulatory requirements, including compliance with healthcare laws such as the federal Anti-Kickback Statute and the False Claims Act. Pharmaceutical manufacturers engage with prescribers, purchasers, and formulary managers in their business arrangements. Federal enforcement agencies monitor product and patient assistance programs, including reimbursement and co-pay support services, which can influence the marketing and sales of these products.
Sources:
Esperion Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Esperion Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Esperion Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
54.17 %